Gordon, Michael S <br/><br/>
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Sep 2006 
 - 4324-32 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2005.05.4221  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers, Tumor--genetics<br/>Dimerization<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Genes, erbB-2<br/>Humans<br/>Middle Aged<br/>Neoplasm Staging<br/>Ovarian Neoplasms--drug therapy<br/>Predictive Value of Tests<br/>Receptor, ErbB-2--genetics